CHEP+ CV Risk Reduction in Diabetes - Nov 19, 2020 3pm ET

Actions and Detail Panel

Sales Ended

Event Information

Share this event

Date and Time

Location

Location

Online Event

Event description
CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD) - Nov 19 - 3PM ET

About this Event

CHEP+ Clinical Practice Guidelines Program

CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD)

Thursday November 19, 2020 • 3-5PM ET

Presented by: Dr. Sheldon Tobe MD, FRCPC, MScCH (HPTE), FACP, FAHA

Dr. Tobe is a specialist in Hypertension and Nephrology, Division of Nephrology, Sunnybrook Health Sciences Centre, and is the University of Toronto Postgraduate Fellowship Director – Nephrology. He is a Professor in the Faculty of Medicine, University of Toronto and Northern Ontario School of Medicine (NOSM).

LEARNING OBJECTIVES

Upon completion of this case study, participants should be able to:

  • Describe the patient who should be treated with an SGLT2i or GLP-1 RA
  • Explain the rational for this treatment and the potential benefits
  • Describe the steps for initiating and monitoring therapy for patients with diabetes

Accreditation: This Group Learning program has been certified by the Canadian College of Family Physicians for up to 6 Mainpro+ credits for the 2-hour presentation including a practice reflection survey to be completed at 6 weeks post-session.

You will receive an email before the event with the details on how to join using Microsoft Teams Online.

FAQs

• How can I contact the organizer with any questions? To contact the organizer, email: Diane Hua-Stewart at Diane.Hua@sunnybrook.ca / (416) 710-3892.

• To learn more: Please visit the event website: https://www.cchangeguidelines.com/

Date and Time

Location

Online Event

Save This Event

Event Saved